2016 Fiscal Year Final Research Report
Kampo treatment for malignant melanoma
| Project/Area Number |
26460922
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General internal medicine(including psychosomatic medicine)
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 東洋医学 / 漢方薬 / 十全大補湯 / 悪性黒色腫 |
|---|
| Outline of Final Research Achievements |
Medical care in Japan treats cancer patients by fusing western medicine and Kampo medicine. Juzentaihoto (JTT) has also been reported to prevent cancer metastasis and recurrence. In this study, we examined the JTT efficacy for natural killer (NK) cell activity, and on the metastasis characteristics by the combination with the anti PD-1 antibody using melanoma metastasis model mice.
JTT significantly suppressed of mouse malignant melanoma metastasis, B16 cell metastasis, but injection of anti asialo-GM1 antibody into mice abrogated inhibitory action of JTT on tumor cell metastasis. JTT significantly increased Interleukin (IL)-12 and interferon (IFN)-γ level in serum, and NK cell activity. JTT increased inhibitory action of anti PD-1 antibody on B16 cell metastasis. The results suggested that JTT inhibits B16 cell metastasis through NK cell activity. Additionally, therapies of combination with JTT and anti PD-1 antibody appear to be a means of increasing response rates for melanoma.
|
| Free Research Field |
東洋医学
|
